TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.

Qing Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.